Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade

Cancer Research

Volumn 64, Issue 17, 2004, Pages 6137-6143

  Li, Haiqing ^a   Gerald, William L ^b   Benezra, Robert ^a,b,c  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Box 241 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE MARROW CELL; BONE MARROW DERIVED ENDOTHELIAL CELL; CANCER GRADING; CANCER TRANSPLANTATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE; GENE EXPRESSION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; ID GENE; ID1 GENE; ID3 GENE; MOUSE; MOUSE MUTANT; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE TUMOR; STEM CELL; TRANSGENIC ADENOCARCINOMA OF THE MOUSE PROSTATE; TRANSGENIC MOUSE; TUMOR ANGIOGENESIS; TUMOR BLEEDING; TUMOR BLOOD FLOW; TUMOR BLOOD VESSEL; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; ENDOTHELIUM, VASCULAR; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INHIBITOR OF DIFFERENTIATION PROTEIN 2; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

EID: 4344563508     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1287     Document Type: Article

References (26)

1. Ruzinova MB, Benezra R. Id proteins in development, cell cycle and cancer. Trends Cell Biol 2003;13:410-8.
2. Lyden D, Young AZ, Zagzag D, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999;401:670-7.
3. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-201.
4. Ruzinova MB, Schoer RA, Gerald W, et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 2003;4:277-89.
5. de Candia P, Solit DB, Giri D, et al. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci USA 2003;100:12337-42.
6. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-43.
7. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-102.
8. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
9. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
10. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
12. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-35.
13. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481-90.
14. Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002;8:841-9.
15. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417:954-8.
16. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002;109:625-37.
17. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526-8.
18. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001;61:2736-43.
19. Gleason DF. Urologic Pathology: The Prostate. Philadelphia, PA: Lea & Febiger; 1977. p. 171-97.
20. Kattan MW, Zelefsky MJ, Kupelian PA., et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 2003;21:4568-71.
21. Ouyang XS, Wang X, Ling MT, Wong HL, Tsao SW, Wong YC. Id-1 stimulates serum independent prostate cancer cell proliferation through inactivation of p16(INK4a)/pRB pathway. Carcinogenesis 2002;23:721-5.
22. Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002;8:121-7.
23. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
24. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999;5:1032-8.
25. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2003;4:393-403.
26. Hoffman JA, Giraudo E, Singh M, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 2003;4:383-91.